Loss of animal insulin in Canada shows risks for patients

For many individuals living with Type 1 diabetes, the journey to find the right insulin can be fraught with challenges. The story of Kyla Cavaliere, a teenager diagnosed with this condition, serves as a poignant example of the struggles faced by patients who depend on specific types of insulin to manage their health effectively. Her experience underscores a broader issue regarding the accessibility and availability of older insulin products that some patients still rely on.

Understanding the Landscape of Insulin Availability in Canada

In Canada, the landscape for diabetes management has evolved significantly over the years. While modern insulins such as recombinant human insulin and insulin analogues have become the standard, the discontinuation of animal-derived insulin products raises pressing concerns for a minority of patients.

As of now, Wockhardt Ltd., an Indian pharmaceutical company, remains the last manufacturer of porcine insulin worldwide. This type of insulin, derived from pig pancreases, has been a lifeline for patients who do not tolerate more contemporary insulin formulations. However, Wockhardt's recent decision to change the distribution method of its product has sparked a dilemma.

Transitioning to Cartridges: A Complicated Process

With the switch from vials to cartridges, Wockhardt must seek new marketing authorization from Health Canada. Unfortunately, this process comes with a hefty price tag, with fees ranging from $44,269 to nearly $320,000. The company has expressed a willingness to proceed with this transition only if these fees are waived, a request that has yet to receive a definitive response from Health Canada.

“The actual medication is the same. It’s just coming in a different format,” stated Marco Cavaliere, Kyla's father, highlighting the frustration that many families face when navigating the bureaucratic landscape of pharmaceutical regulation.

The Risk of Losing Access to Porcine Insulin

The discontinuation of the Hypurin brand of porcine insulin has left patients like Kyla and their families scrambling for alternatives. With the remaining vials expected to expire, parents are left contemplating desperate measures, such as traveling abroad to secure a supply. This situation highlights a critical gap in the healthcare system where patients are left vulnerable due to a lack of viable options.

• Patients have reported adverse reactions to modern insulins.
• Some individuals require older insulin formulations for effective blood sugar control.
• Access to animal insulin is increasingly restricted, impacting a dwindling patient population.

The Transition from Animal to Human Insulin: A Personal Struggle

Historically, insulin derived from animal sources dominated diabetes treatment until the introduction of human insulin in the 1980s. While recombinant DNA technology revolutionized insulin production, it did not come without its challenges. Many patients who transitioned from animal to human insulin report experiencing significant side effects, including pain and hypo- or hyperglycemia.

Colleen Fuller, a Vancouver-based health researcher, experienced severe complications after switching from porcine to human insulin in the mid-1990s. Her struggle not only highlights the limitations of modern insulin formulations but also emphasizes the need for continued access to alternatives for those who do not thrive on newer options.

A Community in Advocacy: The Fight for Animal Insulin

The plight of patients requiring porcine insulin has galvanized advocacy efforts across Canada. Organizations like Diabetes Canada and Breakthrough T1D are working to ensure that the voices of these patients are heard. Despite the dwindling number of individuals relying on animal insulin—estimates vary between 20 to 100—it remains critical for both patients and advocates to push for access to these essential medications.

Health Canada has stated that it cannot compel any company to market a product if it is deemed unprofitable, creating a barrier for patients who have no alternatives. This regulatory environment raises vital questions about the responsibilities of pharmaceutical companies and regulatory bodies in ensuring the health and safety of all patients.

The Role of Healthcare Providers in Patient Support

Healthcare professionals, including endocrinologists, play a vital role in guiding patients through these transitions. Dr. Breay Paty, president of the Canadian Society of Endocrinology and Metabolism, emphasized the need for diverse therapeutic options to support patient care effectively. This diversity is essential for those who do not respond well to modern insulins.

As the healthcare community navigates this complex landscape, it becomes increasingly important to implement strategies that support patients facing insulin shortages:

• Educating patients about available alternatives.
• Facilitating access to special programs for unapproved medications.
• Encouraging collaborative care between patients and healthcare providers.

Addressing the Supply Chain Issues of Insulin in Canada

The current situation regarding porcine insulin in Canada speaks to a larger issue within the healthcare system. Canada, once a pioneer in insulin discovery, now finds itself dependent on foreign production for its supply of insulin products. This reliance raises concerns about the sustainability and security of diabetes management for Canadian patients.

Glenn Thibeault, executive director of government affairs at Diabetes Canada, emphasizes the urgent need for domestic production capabilities. “We take credit for discovering insulin and changing the world, but we do not make a vial of it in Canada,” he stated, highlighting the irony and urgency of the situation.

What Patients Can Do if They Face Insulin Shortages

For patients who find themselves running low on insulin, immediate action is crucial. Here are some steps to consider:

1. Contact your healthcare provider to discuss alternatives.
2. Explore options through special access programs.
3. Consider reaching out to patient advocacy groups for support.
4. Investigate potential international sources for needed medications.

The Future of Insulin Access in Canada

As the discussion around insulin access continues, it is clear that a multifaceted approach is necessary to address the needs of all patients. Continued advocacy, collaboration between healthcare providers, and support from regulatory bodies will be essential in ensuring that individuals like Kyla have the necessary resources to manage their diabetes effectively.